Mesoblast Ltd Class Action

The Claim

William Roberts Lawyers has filed a class action in the Federal Court against Mesoblast Limited (ASX: MSB) to recover compensation for persons who acquired an interest in Mesoblast shares traded on the Australian Stock Exchange (ASX) in the period from 22 February 2018 to 17 December 2020 (inclusive) (Relevant Period).

Anyone who acquired an interest in Mesoblast’s ASX shares during the Relevant Period may be entitled to compensation for losses arising out of Mesoblast’s alleged breaches of its continuous disclosure obligations and/or misleading and deceptive conduct.

The class action alleges that during the Relevant Period, Mesoblast engaged in unlawful conduct which misled the market about the company’s developmental stem cell product “remestemcel-L”. 

ICP Funding Pty Ltd and Investor Claim Partner Pty Ltd (ICP) are providing funding for the costs of the class action and management services, respectively.

If you acquired an interest in Mesoblast shares during the Relevant Period, you will be notified by the Federal Court in due course of any steps you must take to participate. In the interim, if you wish to express your interest or have any questions about the class action, please contact:

·       Ding Pan, Principal, of our office by email at WR_MSB@williamroberts.com.au or on (02) 9552 2111

·       ICP by email at mesoblast@icp.net.auor phone 1800 26 26 00